Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

iwAL 2023

The 5th International Workshop on Acute Leukemias

25–27 August 2023 | San Diego, CA

Explore presentations by leading experts from iwAL 2023 below. Click here to view the roundtable discussion for each of the sessions.

New research perspectives Controversies New frontiers in MRD BPDCN & MDS/MPN + CMML New therapies and limitations Regulatory endpoints Drug resistance Transplant and immunotherapies

Session 1: New research perspectives in AML

Ravi Majeti

Clonal evolution in AML

Ravi Majeti Stanford University School of Medicine, Stanford, CA, United States

Koichi Takahashi

Predictors of transformation in CHIP and CCUS

Koichi Takahashi The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Courtney DiNardo

Familial leukemia predispositions

Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 2: Controversies in AML

Tapan Kadia

Improving intensive chemo approaches in frontline AML

Tapan Kadia The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Charles Craddock

Which patients should have allogeneic transplants in 2023?

Charles Craddock University of Birmingham, Birmingham, United Kingdom

Eunice Wang

Intensive chemo or HMA+VEN intermediate for younger AML patients

Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

Tara Lin

Optimizing therapy in secondary AML and optimal use of CPX-351

Tara Lin The University of Kansas Cancer Center, Kansas City, KS, United States

Harry Erba

Frontline approaches for FLT3-mutant AML

Harry Erba Duke University, Durham, NC, United States

Session 3: New frontiers in MRD for AML clinical practice

Farhad Ravandi

MRD assessment in non-intensive regimens in AML

Farhad Ravandi The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Maximilian Stahl

MRD assessment in intensive regimens in AML

Maximilian Stahl Dana-Farber Cancer Institute, Boston, MA, United States

Roland Walter

MRD as a clinical endpoint in clinical trials

Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Alexander Perl

Applying MRD techniques in FLT3-mutated AML

Alexander Perl University of Pennsylvania, Philadelphia, PA, United States

Session 4: BPDCN & MDS/MPN + CMML

Anand Patel

Current and new directions for accelerated /BP/transformed MPN

Anand Patel UChicago Medicine, Chicago, IL, United States

Mrinal Patnaik

Future targets and drug development in CMML

Mrinal Patnaik Mayo Clinic, Rochester, MN, United States

Raajit Rampal

Novel targeted agents in MPNs

Raajit Rampal Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Mark Levis

History of development and future directions for FLT3 inhibitors

Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States

Naval Daver

Optimizing doublet and triplet combinations in AML

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Geoffrey Uy

Uproleselan in frontline and R/R AML

Geoffrey Uy Washington University in St. Louis, St. Louis, MO, United States

Session 5: Novel targets, combinations and treatments in AML
Part 1 – new AML therapies and limitations

Ghayas Issa

Menin inhibitors in AML

Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Marina Konopleva

Targeting resistance to venetoclax-based therapies

Marina Konopleva Albert Einstein College of Medicine, New York City, NY, United States

Session 6: Special session on regulatory endpoints in AML

Joseph Wynne

The FDA’s perspective on regulatory endpoints in AML

Joseph Wynne US Food & Drug Administration, Silver Spring, MD, United States

Naval Daver

A clinical investigator’s perspective on endpoints & drug development

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 7: Novel targets, combinations, and treatments in AML
Part 2 – what do we know about drug resistance?

Sanam Loghavi

Genomic landscape and prognostic implications of TP53 mutations in AML

Sanam Loghavi The University of Texas MD Anderson Cancer Center, Houston, TX, United States

David Sallman

p53 reactivators and magrolimab in TP53-mutant MDS/AML

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Session 8: Transplant and immunotherapies in AML

Yngvar Fløisand

Vedolizumab for prophylaxis and treatment of acute GvHD post-alloSCT

Yngvar Fløisand Oslo University Hospital, Olso, Norway

Roland Walter

Which patients with AML in MRD+ CRi should be transplanted?

Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States

David Sallman

Early phase CAR-T and NK cell trials for R/R AML and MDS

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

The continued success of the iwAL meeting is in no small part due to the ongoing funding of supporters, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.

iwAL 2023 has been supported by: